A KHN data analysis finds the door of opportunities connecting Capitol Hill, the federal government, and the drug industry likely spins in Big Pharma’s favour. Exhibit A: Alex Azar.
New start-up companies are constantly commercialising new technologies and services. Genomics is ripe for investment right now.
BGI Genomics and Pacific Biosciences of California have announced an agreement by BGI Genomics to purchase an additional 10 Sequel Systems.
Congenica has announced the appointment of its new Chief Executive Officer David Atkins, Ph.D. He has over 25 years’ experience as a global leader in a broad range of diagnostics and healthcare businesses.
Former drug industry executive, Alex Azar was confirmed by a Senate vote on Wednesday as the next secretary of the Department of Health and Human Services.
Having a stock double in a year is pretty impressive, right? Writing for the Motley Fool, Keith Speights weighs in on three healthcare stocks that have done exactly that.
Drug maker Sanofi are shelling out $11.6 billion for Bioverativ, the hemophilia-focused drugmaker spun off by Biogen just last year.
U.S. researchers are relieved to hear that their government shutdown is finally over. Congress approved legislation on 22 January to fund government operations until 8 February, with U.S. President Donald Trump signing soon after.
This year at SLAS 2018, the Formulatrix will be unveiling a concept for a novel automation platform that offers so many benefits to researchers preparing samples that it is surprising others have not beat them to the punch.
Over the weekend, the U.S. saw its government partially shutdown, after the U.S. Senate failed to advance funding legislation. A large number of science groups are now left figuring out if they can keep working.
What’s blockchain technology, how, and why was it developed, and why is everyone talking about it? Alex Schmid provides us with an overview of challenges blockchain technology can help solve within life sciences, and what about it, that makes it so suitable.
Sick and tired of dealing with generic drug shortages and unpredictable price increases, five large U.S. health systems are taking an unusual step: they’re forming their own nonprofit generic drugmaker.
For some federal health programs, a shuttered government means business as usual. But the congressional impasse over funding will hit others hard.
The European Patent Office (EPO) has revoked a patent granted to the Broad Institute for fundamental aspects of the technology, in the latest installment of the CRISPR patent battle.
For those of you who haven’t experienced the process to secure Food and Drug Administration approval, it can be quite the minefield. Helping to solve those woes is new company Enzyme.com.